Leveraging its proprietary cellular technology, TurtleTree is currently able to create highly functional components naturally found in milk, including lactoferrin, human oligosaccharides (HMOs), and alpha-lactalbumin, all of which have been deemed natural according to the latest ISO standards in Asia.
TurtleTree said it differs from other companies developing cell-based milk because it is able to produce naturally-occurring ingredients found in human breast milk, including HMOs Lactoferrin, and Alpha-Lactalbumin; source a variety of mammalian cells; and its unique “B2B2C” business model that will allow it to scale faster than competitors in the same space.
“We start off the process by obtaining mammary gland cells from various sources, then multiply these cells, after which we put them in our in-house special lactation media — a liquid of various components that is naturally present in living mammals,” said Max Rye, TurtleTree’s cofounder and chief strategist. “The cells then convert this lactation media into milk.”
Rye noted how their upcoming B2B (business-to-business) collaborations using its key ingredients and functional blends will span across infant formulas, sports performance, and nutraceuticals, and these product launches will be enabled by TurtleTree’s in-house microbial expression system.
It recently raised $30 million to continue its pursuit of commercialization.
